Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN RUBINO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1962543280
CMS profile
43312
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,823.22

39 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,012.33 4
Food and Beverage $810.89 35

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN RUBINO

NPI 1962543280 · CMS profile ID 43312

Allopathic & Osteopathic Physicians / Internal Medicine

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

39 matching records · $1,823.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 39 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–39 of 39.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $11.8412/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659250837 CMS
Amarin Pharma Inc. $12.3912/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699282451 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.7511/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681998927 CMS
Merck Sharp & Dohme Corporation $10.7411/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695868903 CMS
AstraZeneca Pharmaceuticals LP $14.0111/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685718589 CMS
AbbVie, Inc. $15.5810/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648088187 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.5910/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700276625 CMS
Novo Nordisk Inc $12.9610/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674975467 CMS
Amgen Inc. $17.1210/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547099 CMS
Astellas Pharma US Inc $20.7110/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655746611 CMS
Janssen Pharmaceuticals, Inc $12.5809/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659250829 CMS
Gilead Sciences, Inc. $12.2809/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681595261 CMS
GlaxoSmithKline, LLC. $11.0108/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671434051 CMS
Amarin Pharma Inc. $16.2208/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699203747 CMS
Lilly USA, LLC $10.9508/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657914525 CMS
Amgen Inc. $13.4307/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547122 CMS
Radius Health, Inc. $17.2007/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683933285 CMS
Daiichi Sankyo Inc. $16.6007/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695326079 CMS
Gilead Sciences, Inc. $17.5106/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681595259 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.3406/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700276627 CMS
Amarin Pharma Inc. $17.7605/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699150335 CMS
Amgen Inc. $12.3605/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547119 CMS
Janssen Pharmaceuticals, Inc $13.9304/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659250819 CMS
PFIZER INC. $47.1304/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673769553 CMS
Merck Sharp & Dohme Corporation $9.3104/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695400809 CMS
Amgen Inc. $13.1303/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547115 CMS
PFIZER INC. $264.0503/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673245891 CMS
PFIZER INC. $224.8703/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673246889 CMS
PFIZER INC. $476.2803/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673246891 CMS
PFIZER INC. $329.9203/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673247255 CMS
AstraZeneca Pharmaceuticals LP $11.3203/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685750651 CMS
Amgen Inc. $13.5103/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547111 CMS
Kowa Pharmaceuticals America, Inc. $10.8402/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630297057 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.3302/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684914617 CMS
Novartis Pharmaceuticals Corporation $17.3402/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659852577 CMS
Merck Sharp & Dohme Corporation $12.8001/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695918117 CMS
Amgen Inc. $13.3501/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547107 CMS
Janssen Pharmaceuticals, Inc $11.2201/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659250815 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.9601/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700276629 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,823.22 39
PY2020 $410.97 28
PY2021 $698.79 47
PY2022 $543.04 31
PY2023 $6,389.49 35
PY2024 $1,915.52 44
PY2025 $1,251.65 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,783,192.12 359
PY2024 Recipient $66,231.01 15
PY2024 Principal investigator $2,510,578.54 317
PY2023 Recipient $6,417.61 4
PY2023 Principal investigator $2,159,960.11 267
PY2022 Principal investigator $2,441,546.83 286
PY2021 Principal investigator $1,166,336.49 169
PY2020 Principal investigator $1,326,147.90 192
PY2019 Principal investigator $636,986.48 193

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

286 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $729.50 12/31/2022 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH LLC
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine No dispute reported 06/30/2026 889828811
Principal investigator 1 Janssen Pharmaceuticals, Inc $12,858.00 12/27/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219365
Principal investigator 1 Bavarian Nordic A/S $55,888.00 12/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246465
Principal investigator 1 PFIZER INC. $8,515.92 12/21/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949776879
Principal investigator 1 PFIZER INC. $8,269.32 12/17/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949777277
Principal investigator 1 Janssen Pharmaceuticals, Inc $36,945.00 12/16/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219378
Principal investigator 1 PFIZER INC. $65,842.20 12/16/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949776547
Principal investigator 1 Bavarian Nordic A/S $27,842.00 12/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246425
Principal investigator 1 PFIZER INC. $123,283.56 12/10/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949776549
Principal investigator 1 Seqirus USA Inc $345.24 12/08/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095035
Principal investigator 1 Seqirus USA Inc $345.24 12/08/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095177
Principal investigator 1 PFIZER INC. $1,182.31 12/07/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949776341
Principal investigator 1 Bavarian Nordic A/S $21,477.00 12/06/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246373
Principal investigator 1 Janssen Pharmaceuticals, Inc $18,048.00 12/05/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219397
Principal investigator 1 PFIZER INC. $44,774.34 12/03/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949776551
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,926.00 12/02/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219389
Principal investigator 1 Bavarian Nordic A/S $44,862.00 12/01/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246357
Principal investigator 1 PFIZER INC. $14,187.72 11/24/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949782533
Principal investigator 1 Seqirus USA Inc $1,179.98 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094865
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094867
Principal investigator 1 Seqirus USA Inc $345.24 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094869
Principal investigator 1 Seqirus USA Inc $1,922.25 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095031
Principal investigator 1 Seqirus USA Inc $215.77 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095033
Principal investigator 1 Seqirus USA Inc $1,179.98 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095119
Principal investigator 1 Seqirus USA Inc $1,179.98 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095121
Principal investigator 1 Seqirus USA Inc $1,179.98 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095123
Principal investigator 1 Seqirus USA Inc $345.24 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095125
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095127
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095129
Principal investigator 1 Seqirus USA Inc $345.24 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095131
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095133
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095135
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095137
Principal investigator 1 Seqirus USA Inc $215.77 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095139
Principal investigator 1 Seqirus USA Inc $215.77 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095141
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095143
Principal investigator 1 Seqirus USA Inc $215.77 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095145
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095147
Principal investigator 1 Seqirus USA Inc $215.77 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095149
Principal investigator 1 Seqirus USA Inc $215.77 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095153
Principal investigator 1 Seqirus USA Inc $345.24 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095155
Principal investigator 1 Seqirus USA Inc $215.77 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095157
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095159
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095161
Principal investigator 1 Seqirus USA Inc $345.24 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095163
Principal investigator 1 Seqirus USA Inc $1,179.98 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095165
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095167
Principal investigator 1 Seqirus USA Inc $345.24 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095169
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095171
Principal investigator 1 Seqirus USA Inc $859.40 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095173
Principal investigator 1 Seqirus USA Inc $345.24 11/24/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095175
Principal investigator 1 PFIZER INC. $37,491.42 11/23/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949782577
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,415.00 11/18/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219361
Principal investigator 1 PFIZER INC. $2,567.70 11/16/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949782579
Principal investigator 1 Bavarian Nordic A/S $27,830.00 11/15/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246437
Principal investigator 1 PFIZER INC. $34,589.76 11/10/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949782505
Principal investigator 1 PFIZER INC. $62,693.94 11/09/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949782507
Principal investigator 1 Bavarian Nordic A/S $8,516.00 11/08/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246397
Principal investigator 1 PFIZER INC. $41,075.34 11/08/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949782531
Principal investigator 1 PFIZER INC. $31,024.37 11/05/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949782529
Principal investigator 1 PFIZER INC. $2,289.60 11/05/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949782617
Principal investigator 1 PFIZER INC. $55.89 11/03/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759259
Principal investigator 1 Bavarian Nordic A/S $34,392.00 11/02/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246369
Principal investigator 1 PFIZER INC. $8,647.44 10/28/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949788031
Principal investigator 1 PFIZER INC. $79.20 10/27/2022 Non-covered Recipient Entity
PMG Research of Raleigh
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949785217
Principal investigator 1 PFIZER INC. $24,018.18 10/27/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949788691
Principal investigator 1 Bavarian Nordic A/S $16,264.00 10/26/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246493
Principal investigator 1 Janssen Pharmaceuticals, Inc $11,680.00 10/26/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219393
Principal investigator 1 PFIZER INC. $74.52 10/22/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759843
Principal investigator 1 Bavarian Nordic A/S $27,716.00 10/18/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246453
Principal investigator 1 PFIZER INC. $55.89 10/14/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759257
Principal investigator 1 Bavarian Nordic A/S $18,804.00 10/12/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246419
Principal investigator 1 PFIZER INC. $12,830.07 10/08/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949790087
Principal investigator 1 Bavarian Nordic A/S $18,172.00 10/07/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246379
Principal investigator 1 PFIZER INC. $1,744.20 10/07/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949790205
Principal investigator 1 PFIZER INC. $241.15 10/04/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759841
Principal investigator 1 PFIZER INC. $144.69 10/03/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759071
Principal investigator 1 PFIZER INC. $74.52 10/03/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759255
Principal investigator 1 PFIZER INC. $1,525.50 10/01/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949790103
Principal investigator 1 PFIZER INC. $37.26 09/29/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759373
Principal investigator 1 Bavarian Nordic A/S $17,488.00 09/28/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246505
Principal investigator 1 PFIZER INC. $37.26 09/28/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759555
Principal investigator 1 PFIZER INC. $35,520.51 09/28/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949789981
Principal investigator 1 PFIZER INC. $4,470.63 09/28/2022 Non-covered Recipient Entity
Accellacare of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949790107
Principal investigator 1 Janssen Pharmaceuticals, Inc $760.00 09/26/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219301
Principal investigator 1 Bavarian Nordic A/S $3,926.00 09/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246487
Principal investigator 1 Bavarian Nordic A/S $4,289.00 09/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246515
Principal investigator 1 Becton, Dickinson and Company $3,500.00 09/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
SUST030 No dispute reported 06/30/2026 929560161
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,386.00 09/23/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219305
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $871.43 09/22/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933400701
Principal investigator 1 PFIZER INC. $3,204.90 09/22/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949789979
Principal investigator 1 PFIZER INC. $257,850.94 09/22/2022 Non-covered Recipient Entity
Accellacare of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949790105
Principal investigator 1 PFIZER INC. $11,320.00 09/22/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949790165
Principal investigator 1 Bavarian Nordic A/S $20,246.00 09/20/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246459
Principal investigator 1 PFIZER INC. $241.15 09/19/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759375
Principal investigator 1 PFIZER INC. $18.63 09/16/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759193
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,082.39 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933400380
Principal investigator 1 Seqirus USA Inc $1,179.98 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094857
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094859
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094861
Principal investigator 1 Seqirus USA Inc $1,922.25 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094863
Principal investigator 1 Seqirus USA Inc $1,179.98 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095045
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095047
Principal investigator 1 Seqirus USA Inc $1,179.98 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095049
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095051
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095053
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095055
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095057
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095059
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095061
Principal investigator 1 Seqirus USA Inc $1,922.25 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095063
Principal investigator 1 Seqirus USA Inc $1,179.98 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095065
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095067
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095069
Principal investigator 1 Seqirus USA Inc $1,179.98 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095071
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095073
Principal investigator 1 Seqirus USA Inc $1,922.25 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095075
Principal investigator 1 Seqirus USA Inc $1,179.98 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095077
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095079
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095081
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095083
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095085
Principal investigator 1 Seqirus USA Inc $1,922.25 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095087
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095089
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095091
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095093
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095095
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095097
Principal investigator 1 Seqirus USA Inc $1,922.25 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095099
Principal investigator 1 Seqirus USA Inc $1,922.25 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095101
Principal investigator 1 Seqirus USA Inc $1,179.98 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095103
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095105
Principal investigator 1 Seqirus USA Inc $1,922.25 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095107
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095109
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095111
Principal investigator 1 Seqirus USA Inc $859.40 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095113
Principal investigator 1 Seqirus USA Inc $1,922.25 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095115
Principal investigator 1 Seqirus USA Inc $215.77 09/15/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883095117
Principal investigator 1 Bavarian Nordic A/S $1,666.00 09/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246431
Principal investigator 1 PFIZER INC. $144.69 09/13/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759189
Principal investigator 1 PFIZER INC. $96.46 09/12/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759553
Principal investigator 1 Bavarian Nordic A/S $44,779.00 09/07/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246385
Principal investigator 1 PFIZER INC. $48.23 09/06/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759191
Principal investigator 1 PFIZER INC. $144.69 08/29/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759371
Principal investigator 1 Janssen Pharmaceuticals, Inc $9,708.00 08/26/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219297
Principal investigator 1 PFIZER INC. $3,078.00 08/24/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949801081
Principal investigator 1 Bavarian Nordic A/S $2,704.00 08/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246483
Principal investigator 1 Bavarian Nordic A/S $23,223.00 08/22/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246477
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,713.15 08/18/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933398337
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,713.15 08/18/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933398345
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $1,713.15 08/18/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933398355
Principal investigator 1 Bavarian Nordic A/S $15,264.00 08/17/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246447
Principal investigator 1 PFIZER INC. $2,693.96 08/17/2022 Non-covered Recipient Entity
Accellacare of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949800947
Principal investigator 1 PFIZER INC. $540.00 08/17/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949804581
Principal investigator 1 Seqirus USA Inc $41.20 08/17/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094855
Principal investigator 1 Bavarian Nordic A/S $8,476.00 08/11/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246407
Principal investigator 1 Bavarian Nordic A/S $45,510.00 08/09/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246403
Principal investigator 1 PFIZER INC. $289.38 08/08/2022 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759551
Principal investigator 1 PFIZER INC. $1,838.70 08/05/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949803095
Principal investigator 1 PFIZER INC. $2,430.00 08/04/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949801129
Principal investigator 1 PFIZER INC. $624.81 08/03/2022 Non-covered Recipient Entity
Accellacare of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949802375
Principal investigator 1 Bavarian Nordic A/S $36,903.00 08/02/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246363
Principal investigator 1 Bavarian Nordic A/S $15,496.00 07/27/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246499
Principal investigator 1 Janssen Pharmaceuticals, Inc $16,824.00 07/22/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219293
Principal investigator 1 Bavarian Nordic A/S $27,994.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246471
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,256.22 07/21/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933394453
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283609
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283615
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283621
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283627
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283633
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283639
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283645
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283651
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947283657
Principal investigator 1 PFIZER INC. $4,050.00 07/20/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949806349
Principal investigator 1 Seqirus USA Inc $1,609.00 07/18/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094853
Principal investigator 1 PFIZER INC. $540.00 07/13/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949806535
Principal investigator 1 Bavarian Nordic A/S $19,760.00 07/12/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246413
Principal investigator 1 PFIZER INC. $375.00 07/12/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949790261
Principal investigator 1 PFIZER INC. $65.00 07/12/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949790263
Principal investigator 1 PFIZER INC. $4,055.40 07/09/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949807061
Principal investigator 1 Bavarian Nordic A/S $23,712.00 07/08/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246391
Principal investigator 1 Seqirus USA Inc $306.00 07/06/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094845
Principal investigator 1 Seqirus USA Inc $221.15 07/06/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094847
Principal investigator 1 Seqirus USA Inc $74.16 07/06/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094849
Principal investigator 1 Seqirus USA Inc $177.19 07/06/2022 Non-covered Recipient Entity
Pmg Research
A Phase 2, Randomized, Study to Evaluate Safety and Immunogenicity of One or Two Heterologous Booster Vaccinations With an MF59-adjuvanted, Cell Culture-derived H5N6 Influenza Vaccine in Adults Primed With MF59- adjuvanted, Cell Culture-derived H5N1 Influenza Vaccine or Unprimed. No dispute reported 06/30/2026 883094851
Principal investigator 1 Bavarian Nordic A/S $69,160.00 06/30/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246510
Principal investigator 1 PFIZER INC. $5,793.62 06/30/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949813001
Principal investigator 1 PFIZER INC. $1,525.50 06/30/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949813201
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,744.27 06/23/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933391535
Principal investigator 1 Bavarian Nordic A/S $5,928.00 06/22/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907247165
Principal investigator 1 PFIZER INC. $2,805.30 06/22/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949813253
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273253
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273259
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273265
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273271
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273277
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273283
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273289
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273295
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273301
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273307
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273311
Principal investigator 1 Esperion Therapeutics, Inc. $1,373.00 06/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947273317
Principal investigator 1 Janssen Pharmaceuticals, Inc $20,540.00 06/20/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219171
Principal investigator 1 Bavarian Nordic A/S $1,976.00 06/16/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246441
Principal investigator 1 PFIZER INC. $425.00 06/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949790085
Principal investigator 1 PFIZER INC. $65.00 06/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949790279
Principal investigator 1 PFIZER INC. $2,230.00 06/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949790281
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,000.00 06/03/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219167
Principal investigator 1 PFIZER INC. $3,677.40 06/03/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949813329
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $14,549.04 05/26/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933388773
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $11,533.65 05/26/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933388787
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,397.29 05/26/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933388811
Principal investigator 1 PFIZER INC. $92.40 05/26/2022 Non-covered Recipient Entity
PMG Research of Raleigh
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949823983
Principal investigator 1 PFIZER INC. $413.83 05/25/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949749709
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 05/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947265211
Principal investigator 1 PFIZER INC. $1,350.00 05/21/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949749715
Principal investigator 1 PFIZER INC. $5,329.80 05/21/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949749719
Principal investigator 1 Janssen Pharmaceuticals, Inc $99,542.00 05/20/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219163
Principal investigator 1 PFIZER INC. $4,363.20 05/06/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949750163
Principal investigator 1 PFIZER INC. $3,192.75 05/06/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949750169
Principal investigator 1 PFIZER INC. $6,360.00 05/03/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949750157
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/25/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262233
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/25/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262239
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/25/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262245
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/25/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262253
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/25/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262257
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 04/25/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947262263
Principal investigator 1 Janssen Pharmaceuticals, Inc $34,011.00 04/25/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219159
Principal investigator 1 PFIZER INC. $3,510.00 04/22/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949822535
Principal investigator 1 PFIZER INC. $3,491.10 04/21/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949822351
Principal investigator 1 PFIZER INC. $413.83 04/20/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949822047
Principal investigator 1 PFIZER INC. $1,655.32 04/19/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949822353
Principal investigator 1 PFIZER INC. $92.40 04/12/2022 Non-covered Recipient Entity
PMG Research of Raleigh
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949824805
Principal investigator 1 PFIZER INC. $376.65 04/01/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949822349
Principal investigator 1 PFIZER INC. $2,386.80 03/31/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949826145
Principal investigator 1 Janssen Pharmaceuticals, Inc $8,044.00 03/28/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219123
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257737
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257747
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257757
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257767
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257775
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257785
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257795
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257806
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257815
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257825
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257835
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257843
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257853
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257863
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257873
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257883
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257893
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257903
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257913
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257921
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257931
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257941
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257951
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257961
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947257969
Principal investigator 1 Esperion Therapeutics, Inc. $600.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947258057
Principal investigator 1 Esperion Therapeutics, Inc. $200.00 03/24/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 947258067
Principal investigator 1 PFIZER INC. $413.83 03/22/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949826143
Principal investigator 1 Janssen Pharmaceuticals, Inc $104,110.00 03/18/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219119
Principal investigator 1 PFIZER INC. $827.66 03/08/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949826095
Principal investigator 1 PFIZER INC. $8,002.80 03/03/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949826093
Principal investigator 1 PFIZER INC. $7,321.05 03/03/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949826141
Principal investigator 1 PFIZER INC. $6,302.13 03/01/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949826091
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $3,881.85 02/24/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933380897
Principal investigator 1 Janssen Pharmaceuticals, Inc $141,594.00 02/16/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219115
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $4,362.15 02/10/2022 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933379847
Principal investigator 1 PFIZER INC. $11,996.10 02/04/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949826905
Principal investigator 1 PFIZER INC. $2,482.98 02/01/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949826907
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $2,500.00 01/28/2022 Non-covered Recipient Entity
PMG RESEARCH INC
BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine No dispute reported 06/30/2026 933378675
Principal investigator 1 Biohaven Pharmaceutical Holding Company Ltd. $6,178.19 01/27/2022 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention No dispute reported 06/30/2026 933378109
Principal investigator 1 Janssen Pharmaceuticals, Inc $52,826.00 01/21/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219111
Principal investigator 1 PFIZER INC. $2,896.81 01/19/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949828239
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,126.56 01/15/2022 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH TQJ230 ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 909410649
Principal investigator 1 PFIZER INC. $5,313.10 01/14/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949831165
Principal investigator 1 PFIZER INC. $17,600.00 01/12/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949828313
Principal investigator 1 PFIZER INC. $1,795.50 01/08/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949828345
Principal investigator 1 PFIZER INC. $1,094.85 01/08/2022 Non-covered Recipient Entity
PMG Research Inc
A 26WEEK PHASE 2B 2PART RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED PARALLEL GROUP DOSERANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF06882961 ADMINISTRATION IN ADULTS WITH OBESITY No dispute reported 06/30/2026 949831167